Electroconvulsive Therapy (ECT): Modern Practice, Efficacy, Cognitive Effects, Informed Consent, and Clinical Indications

Electroconvulsive therapy (ECT) remains the most acutely effective treatment in biological psychiatry for severe mood disorders, yet it continues to occupy a paradoxical position — simultaneously underutilized due to persistent stigma and widely acknowledged by treatment guidelines as a first-line intervention for specific clinical presentations. Since its introduction by Cerletti and Bini in 1938, ECT has undergone radical transformation in technique, safety, and understanding of mechanism. Modern ECT bears little resemblance to the unmodified procedures depicted in popular culture; it is administered under general anesthesia with neuromuscular blockade, continuous physiological monitoring, and increasingly sophisticated stimulus dosing strategies.

Globally, ECT utilization rates vary enormously — from approximately 1–5 per 10,000 population per year in the United States and parts of Western Europe to negligible use in some low- and middle-income countries and, conversely, higher but less well-documented rates in parts of Asia. In the United States, estimates suggest approximately 100,000 individuals receive ECT annually, though precise national registries are lacking. The American Psychiatric Association (APA), the National Institute for Health and Care Excellence (NICE), and the Royal Australian and New Zealand College of Psychiatrists all endorse ECT for specific indications, particularly treatment-resistant depression (TRD), catatonia, and acute suicidality.

This article provides a detailed clinical review of modern ECT practice, covering its neurobiological mechanisms, clinical indications, comparative efficacy, cognitive effects, informed consent considerations, and prognostic factors. It draws on landmark studies, meta-analytic evidence, and current clinical guidelines to present an evidence-based account that goes substantially beyond introductory overviews.

Despite decades of research, the precise neurobiological mechanisms by which ECT produces its therapeutic effects remain incompletely understood. However, a convergence of neuroimaging, neurochemical, neuroendocrine, and molecular evidence points to multiple overlapping mechanisms rather than a single unitary process.

Neurotransmitter Systems

ECT exerts broad effects on monoaminergic neurotransmission. Serotonergic function is enhanced through increased 5-HT_1A receptor sensitivity and downstream signaling in the raphe nuclei. Dopaminergic transmission is augmented, particularly in the mesolimbic and mesocortical pathways — an effect hypothesized to underlie its efficacy in psychomotor retardation and anhedonia. Noradrenergic tone is enhanced via increased release and postsynaptic receptor sensitivity. Beyond monoamines, ECT modulates GABAergic and glutamatergic transmission; preclinical data demonstrate increased GABA concentrations in cortical regions following repeated seizures, which may contribute to the anticonvulsant properties that develop over a treatment course (the so-called "anticonvulsant hypothesis" of ECT's mechanism). Magnetic resonance spectroscopy (MRS) studies in humans have confirmed increases in cortical GABA levels following ECT.

Neurotrophic and Neuroplasticity Effects

One of the most robust findings in ECT neurobiology is the upregulation of brain-derived neurotrophic factor (BDNF). Meta-analyses have demonstrated significant increases in serum BDNF levels following ECT courses, with effect sizes in the moderate-to-large range (Hedges' g ≈ 0.6–0.8). ECT promotes hippocampal neurogenesis in animal models — a finding replicated across multiple species and paradigms. Structural MRI studies in humans consistently demonstrate volume increases in the hippocampus, amygdala, and anterior cingulate cortex following ECT, typically in the range of 1–5% volumetric increase. The landmark study by Nordanskog et al. (2010) first documented bilateral hippocampal volume increases following ECT using high-resolution MRI, a finding subsequently replicated in larger samples. Importantly, whether these volumetric changes reflect true neurogenesis, dendritic branching, synaptogenesis, angiogenesis, or glial proliferation in humans remains debated.

Neuroendocrine and Immune Modulation

ECT normalizes hypothalamic-pituitary-adrenal (HPA) axis dysregulation, with documented reductions in cortisol hypersecretion and normalization of dexamethasone suppression test (DST) results in treatment responders. There is evidence for modulation of pro-inflammatory cytokines, including reductions in IL-6, TNF-α, and IL-1β, suggesting an anti-inflammatory mechanism that may be particularly relevant given the neuroinflammatory hypothesis of depression.

Functional Connectivity and Circuit-Level Effects

Resting-state fMRI studies demonstrate that ECT modulates functional connectivity within the default mode network (DMN), the salience network, and cortico-limbic circuits. Specifically, ECT appears to normalize hyperconnectivity between the dorsolateral prefrontal cortex (DLPFC) and the subgenual anterior cingulate cortex (sgACC, Brodmann area 25) — a circuit implicated in rumination and negative self-referential processing. These circuit-level changes parallel clinical improvement, suggesting a direct relationship between network normalization and symptom resolution.

Genetic Factors

Pharmacogenomic research on ECT response is in early stages. Preliminary evidence suggests that polymorphisms in the BDNF Val66Met gene, the serotonin transporter gene (SLC6A4), and genes involved in synaptic plasticity (e.g., NTRK2) may moderate treatment response. However, no genetic variant has achieved sufficient predictive validity for clinical application. A genome-wide association study (GWAS) by the Global ECT-MRI Research Collaboration (GEMRIC) consortium is underway to identify genetic markers of ECT response.

ECT has established indications across several psychiatric conditions. The APA (2001) practice guidelines and subsequent updates, along with NICE guidelines, define the primary indications as follows:

Major Depressive Disorder (MDD)

ECT is most commonly administered for severe MDD, particularly when characterized by treatment resistance, psychotic features, catatonic features, or acute suicidality. The DSM-5-TR defines treatment-resistant depression as failure to respond to two or more adequate antidepressant trials, though clinical practice often reserves ECT for patients who have failed three or more medication trials (the definition used in the STAR*D trial's third step). ECT is considered a first-line treatment — not merely a last resort — in the following scenarios:

• Psychotic depression: ECT demonstrates superiority over pharmacotherapy alone, with remission rates of 80–90% compared to approximately 40–50% for combined antidepressant-antipsychotic regimens
• Acute suicidality with imminent risk: ECT provides the fastest resolution of suicidal ideation of any available treatment, with significant reduction often observed within 1–2 weeks
• Catatonic features: ECT is effective in 80–100% of catatonia cases across etiologies
• Medical conditions requiring rapid resolution: Such as severe nutritional compromise due to food refusal, or pregnancy where medication risks are unacceptable

Bipolar Disorder

ECT is effective for both bipolar depression and acute mania. For bipolar depression, response rates are comparable to those in unipolar depression (approximately 50–70%). For acute mania, ECT demonstrates response rates of approximately 80%, and randomized evidence (including the study by Mukherjee et al., 1994) supports its efficacy in medication-resistant mania. ECT is also effective in mixed episodes, which are often refractory to pharmacotherapy.

Schizophrenia and Schizoaffective Disorder

ECT has a more circumscribed role in schizophrenia. It is most effective as an augmentation strategy when combined with antipsychotics in treatment-resistant schizophrenia (TRS), particularly for positive symptoms and catatonia. The landmark study by Petrides et al. (2015) demonstrated that clozapine plus ECT produced response rates of approximately 50% in patients who had failed clozapine monotherapy — a remarkable finding in a population where further pharmacological options are extremely limited. ECT is less effective for chronic negative symptoms and cognitive deficits of schizophrenia.

Catatonia

Regardless of underlying etiology — mood disorder, schizophrenia, general medical condition, or autism spectrum disorder — ECT is the definitive treatment for catatonia that does not respond to benzodiazepines. Response rates of 80–100% are consistently reported. Given the potentially life-threatening nature of malignant catatonia, ECT should be considered early rather than after prolonged benzodiazepine failure.

Other Indications

Emerging or less established indications include treatment-resistant obsessive-compulsive disorder (limited evidence), Parkinson's disease with co-occurring depression or psychosis (ECT improves both motor and psychiatric symptoms), neuroleptic malignant syndrome (especially overlapping with catatonia), and refractory status epilepticus (paradoxically, ECT can terminate refractory seizures through its anticonvulsant properties).

The evidence base for ECT's efficacy is extensive, though the nature of the intervention makes placebo-controlled trials methodologically challenging. Sham-controlled studies — in which anesthesia is administered without electrical stimulation — have been conducted, and meta-analyses of these trials consistently demonstrate ECT's superiority.

Acute Efficacy in Major Depression

The UK ECT Review Group (2003) meta-analysis, published in The Lancet, pooled data from six randomized controlled trials comparing real versus sham ECT and found a standardized mean difference (SMD) of –0.91 (95% CI: –1.27 to –0.54) favoring real ECT — a large effect size. Response rates (typically defined as ≥50% reduction in Hamilton Depression Rating Scale scores) in ECT-treated samples range from 50–70% in treatment-resistant populations and up to 80–90% in non-resistant or psychotic depression. Remission rates (defined as achievement of a specified low score threshold) range from 30–50% in treatment-resistant populations and 60–80% in less resistant presentations.

The number needed to treat (NNT) for ECT versus sham in acute depression is approximately 3–4, which compares favorably to virtually all other treatments in psychiatry. For context, the NNT for SSRIs versus placebo in moderate depression is approximately 7–8.

ECT vs. Pharmacotherapy

Randomized trials directly comparing ECT to pharmacotherapy consistently favor ECT. The Janicak et al. (1985) meta-analysis found ECT superior to tricyclic antidepressants (effect size d ≈ 0.4), MAOIs (d ≈ 0.5), and simulated ECT (d ≈ 0.7). More recent naturalistic and quasi-experimental studies confirm these findings, though head-to-head randomized comparisons with modern antidepressants (SSRIs, SNRIs) are limited by ethical considerations — it is generally considered unethical to randomize severely ill patients to medication alone when ECT is available.

ECT vs. Ketamine/Esketamine

The landmark ELEKT-D trial (Anand et al., 2023), published in the New England Journal of Medicine, was the first large-scale, randomized, non-inferiority trial comparing ECT to intravenous ketamine for treatment-resistant depression without psychotic features. The study enrolled 403 patients and found that ketamine was non-inferior to ECT on the primary outcome (QIDS-SR-16 score at 3 weeks), with response rates of 55.4% for ketamine versus 41.2% for ECT — a surprising finding that favored ketamine. However, this trial has important limitations: it excluded psychotic depression (where ECT is most effective), used right unilateral ECT at threshold-level dosing (which may underestimate ECT's efficacy compared to suprathreshold dosing), and had a 3-week follow-up that may not capture ECT's full treatment course. The study generated significant debate and has not altered guideline recommendations that position ECT as the gold standard for severe, treatment-resistant depression.

ECT vs. Transcranial Magnetic Stimulation (TMS)

Head-to-head comparisons of ECT and repetitive TMS (rTMS) generally favor ECT, particularly for severe depression. A meta-analysis by Ren et al. (2014) found ECT superior to rTMS with an odds ratio of approximately 4.2 for response. However, TMS has a more favorable side effect profile, particularly regarding cognitive effects, and is increasingly used as an intermediate step before ECT. Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), a novel accelerated theta-burst TMS protocol, has shown promising remission rates (approximately 79% in the open-label pilot by Cole et al., 2020) but requires replication in larger, controlled trials.

Relapse Prevention and Maintenance ECT

Relapse following successful acute ECT is a major clinical concern. Without continuation treatment, relapse rates in the 6 months following ECT range from 50–80%. The Sackeim et al. (2001) continuation pharmacotherapy trial demonstrated that nortriptyline plus lithium significantly reduced relapse to 39% over 24 weeks, compared to 60% for nortriptyline alone and 84% for placebo. Maintenance ECT (M-ECT) — typically administered at intervals of 1–4 weeks — is an alternative continuation strategy. The PRIDE study (Kellner et al., 2016) demonstrated that M-ECT combined with venlafaxine produced a sustained remission rate of approximately 46% at 6 months, establishing the current evidence-based paradigm for post-ECT continuation care.

The therapeutic effects and side effect profile of ECT are profoundly influenced by technical parameters, and understanding these is essential for interpreting outcome data and for informed clinical decision-making.

Electrode Placement

Three primary electrode placements are used in contemporary practice:

• Right unilateral (RUL): Electrodes placed over the right hemisphere (d'Elia placement — one electrode at the vertex, one over the right temporal region). RUL ECT at suprathreshold dosing (typically 6× seizure threshold) produces efficacy comparable to bilateral ECT with significantly fewer cognitive side effects. This is the most commonly recommended initial approach in modern guidelines.
• Bilateral bitemporal (BT): Electrodes placed over both temporal regions. BT ECT is the traditional placement, associated with robust efficacy but greater cognitive side effects, particularly retrograde amnesia. It remains the preferred approach for patients with catatonia, acute mania, or severe suicidality requiring the most rapid response.
• Bifrontal (BF): Electrodes placed over both frontal regions. BF ECT may offer a compromise between efficacy and cognitive effects, though data are less extensive than for RUL or BT placements. The EFFECT trial (Semkovska et al., 2016) found BF ECT comparable to BT ECT in efficacy with potentially fewer cognitive side effects, though confidence intervals were wide.

Stimulus Dosing

Stimulus dose is expressed relative to the individual's seizure threshold (ST), which is determined empirically at the first session by dose titration. Key dosing principles include:

• RUL ECT requires suprathreshold dosing — typically 5–8× ST — to achieve adequate efficacy. At 1–1.5× ST, RUL ECT is no more effective than sham, as demonstrated by Sackeim et al. (2000) in a landmark four-cell randomized trial.
• BT ECT is effective at 1.5–2.5× ST, though higher doses may improve speed of response at the cost of increased cognitive effects.
• Brief pulse (0.5–1.0 ms pulse width) is standard practice. Ultra-brief pulse (0.3 ms) ECT, particularly in the RUL configuration, further reduces cognitive side effects while maintaining efficacy at high suprathreshold doses (typically 8× ST), as demonstrated by the randomized trial by Sackeim et al. (2008).

Treatment Course and Session Frequency

An acute ECT course typically involves 6–12 sessions administered 2–3 times per week. Twice-weekly treatment produces equivalent overall efficacy with fewer cognitive side effects compared to thrice-weekly administration, as shown by the study by Shapira et al. (1998), and is increasingly preferred. The median number of sessions to achieve remission is approximately 7–9, though individual variation is substantial. Clinical response is typically monitored using standardized depression rating scales (e.g., PHQ-9, MADRS, HAM-D) at each session or weekly.

Cognitive side effects are the primary limitation of ECT and the most frequent source of patient concern. A nuanced understanding of these effects — their type, severity, time course, and predictors — is essential for both clinical practice and informed consent.

Acute Cognitive Effects

Immediately following each ECT session, patients experience a period of postictal confusion lasting minutes to hours. During this acute phase, disorientation, attentional deficits, and anterograde amnesia are universal. The duration and severity of postictal confusion are influenced by electrode placement (BT > BF > RUL), stimulus dose, and individual patient factors.

Anterograde Amnesia

Difficulty forming new memories during the course of ECT treatment is common but typically resolves within days to weeks of completing the treatment course. Meta-analytic data (Semkovska & McLoughlin, 2010) indicate that anterograde memory function returns to or exceeds baseline levels within 15 days of completing ECT for most patients, and cognitive performance on objective neuropsychological testing actually improves relative to pre-ECT baseline at longer follow-up intervals — likely reflecting the resolution of depression-related cognitive impairment.

Retrograde Amnesia

Loss of memories formed before ECT is the most clinically significant cognitive effect. Retrograde amnesia follows a temporal gradient — memories formed closer to the time of treatment are more vulnerable than remote memories. Autobiographical memory (memory for personal events) is more affected than impersonal semantic memory (general knowledge). The Sackeim et al. (2007) Columbia University study remains one of the most comprehensive assessments of ECT's cognitive effects; it found that bilateral electrode placement, sine-wave stimulation (no longer used), and greater number of treatments were the strongest predictors of persistent retrograde amnesia at 6-month follow-up.

The critical clinical question is whether ECT produces permanent memory loss. This remains contested. Objective neuropsychological testing in most studies shows recovery to baseline or above by 1–6 months post-ECT. However, a subset of patients — estimated at 10–30% depending on the study and methodology — report persistent subjective memory complaints even when objective testing is normal. Whether these subjective complaints represent genuine subtle memory impairment below the detection threshold of standard tests, the effects of ongoing depression, or a psychological attribution remains debated. The autobiographical memory interview (AMI) and the Columbia University autobiographical memory interview–short form (CUAMI-SF) are specialized instruments that may capture ECT-related memory changes more sensitively than standard neuropsychological batteries.

Predictors of Cognitive Side Effects

• Electrode placement: Bilateral > bifrontal > right unilateral (strongest predictor)
• Stimulus waveform: Sine wave (obsolete) >> brief pulse > ultra-brief pulse
• Stimulus dose: Higher dose relative to threshold increases cognitive risk
• Number of treatments: More sessions associated with greater cumulative cognitive effects
• Session frequency: Thrice-weekly > twice-weekly
• Age: Older patients are more vulnerable to cognitive effects
• Pre-existing cognitive impairment: Baseline cognitive deficits predict greater post-ECT cognitive difficulty
• Concurrent psychotropic medications: Lithium, benzodiazepines (raise seizure threshold and may reduce efficacy), and anticholinergic medications increase cognitive risk

Structural Brain Effects

Concerns about ECT causing "brain damage" are not supported by modern evidence. Structural MRI studies consistently show no evidence of cortical atrophy, white matter lesions, or other markers of brain injury following ECT. The volumetric increases observed in the hippocampus and amygdala are interpreted as reflecting neuroplasticity rather than pathological edema. Animal studies using modern ECT parameters (electroconvulsive stimulation, or ECS, in rodents) demonstrate no neuronal loss on histological examination.

Modern ECT is one of the safest procedures performed under general anesthesia. Mortality rates are estimated at approximately 1 per 73,000–80,000 treatments (approximately 1 per 10,000 patients per treatment course), which is comparable to the risk of general anesthesia for minor procedures and substantially lower than the mortality risk of untreated severe depression.

Anesthetic and Procedural Protocol

Standard anesthetic management includes:

• Induction agent: Methohexital (0.5–1.0 mg/kg IV) is considered the gold standard due to its minimal effect on seizure threshold. Propofol is an alternative but raises the seizure threshold, potentially reducing ECT efficacy. Etomidate may be used when seizure adequacy is difficult to achieve, as it has minimal anticonvulsant properties, though it inhibits adrenal function with repeated dosing. Ketamine as an induction agent has been investigated as a potential way to enhance ECT's antidepressant effect, but meta-analyses (e.g., McGirr et al., 2015) have not found consistent added benefit for depression outcomes.
• Muscle relaxant: Succinylcholine (0.5–1.0 mg/kg IV) provides neuromuscular blockade to prevent musculoskeletal injury during the seizure. Rocuronium with sugammadex reversal is an alternative for patients with pseudocholinesterase deficiency or other contraindications to succinylcholine.
• Ventilation: Pre-oxygenation with 100% oxygen and assisted ventilation throughout the procedure minimize hypoxic risk.
• Monitoring: ECG, pulse oximetry, blood pressure, EEG (to assess seizure quality and duration), and EMG (typically using a cuff technique on one extremity to observe motor seizure while the rest of the body is paralyzed).

Contraindications

There are no absolute contraindications to ECT, a point frequently emphasized in guidelines. The only commonly cited near-absolute contraindication is pheochromocytoma (risk of hypertensive crisis). Relative contraindications requiring careful risk-benefit analysis include:

• Raised intracranial pressure (particularly with space-occupying lesions — risk of herniation due to transient further increase in ICP during seizure)
• Recent cerebrovascular accident (typically within 1–3 months)
• Unstable aneurysm (aortic or cerebral)
• Unstable angina or recent myocardial infarction
• Retinal detachment
• Cochlear implants (require coordination with ENT; not an absolute contraindication)

Cardiac complications are the most common serious adverse events, accounting for the majority of ECT-related morbidity and mortality. The parasympathetic surge during stimulus delivery (producing transient bradycardia or asystole) followed by sympathetic activation during the seizure (producing tachycardia and hypertension) creates hemodynamic stress. Atropine or glycopyrrolate may be administered prophylactically in patients with prominent bradycardia, and short-acting beta-blockers or antihypertensives may be needed for post-seizure hypertension.

Informed consent for ECT requires particular clinical and ethical attention given the treatment's historical associations, its cognitive side effects, and the frequent impairment in decision-making capacity among patients for whom ECT is indicated (e.g., severe depression with psychosis, catatonia).

Elements of Informed Consent

A thorough informed consent process for ECT should include discussion of:

• The nature and purpose of the procedure, including a basic description of what occurs during a treatment session
• Expected benefits, including approximate response and remission rates relevant to the patient's diagnosis
• Risks, with specific attention to cognitive effects — both short-term (postictal confusion, anterograde amnesia) and the possibility of retrograde amnesia, including the low but real possibility of persistent autobiographical memory gaps
• Medical risks including those associated with general anesthesia, headache (reported in approximately 25–45% of sessions), nausea, myalgia, and rare cardiac events
• The number and frequency of treatments anticipated, and the need for continuation/maintenance treatment after acute response
• Alternative treatments available, including pharmacotherapy, psychotherapy, TMS, esketamine, and vagus nerve stimulation
• The right to withdraw consent at any time

Capacity Assessment

Many patients referred for ECT have impaired decision-making capacity due to the severity of their illness. Depression-related executive dysfunction, psychotic symptoms, catatonia, and severe cognitive slowing can all compromise a patient's ability to understand, appreciate, reason about, and communicate treatment decisions. When capacity is impaired, surrogate decision-making through a healthcare proxy, legal guardian, or, in some jurisdictions, judicial authorization may be required. Importantly, the presence of depression alone does not imply incapacity — capacity must be assessed individually, ideally using structured instruments such as the MacArthur Competence Assessment Tool for Treatment (MacCAT-T).

Involuntary ECT

The legal framework for involuntary ECT varies dramatically by jurisdiction. In many U.S. states, involuntary ECT requires judicial authorization even when a patient is under involuntary psychiatric commitment. In some European countries, emergency ECT for life-threatening conditions (e.g., malignant catatonia, lethal refusal of nutrition) may be administered under mental health legislation without a separate judicial process. The ethical principle underlying involuntary ECT in all frameworks is that the intervention serves the patient's best interest when the condition is life-threatening and the patient lacks capacity to make treatment decisions.

Consent as an Ongoing Process

Informed consent for ECT should be understood as an ongoing process rather than a single event. Patients should be re-engaged in consent discussions as the treatment course progresses, particularly if cognitive side effects emerge, if the treatment is not producing expected benefits, or if the patient's clinical state and capacity change.

Identifying patients most likely to benefit from ECT is clinically important for treatment selection and for setting realistic expectations.

Positive Predictors of ECT Response

• Psychotic features: The single strongest predictor of ECT response in depression. Psychotic depression responds to ECT at rates of 80–90%, substantially higher than non-psychotic TRD (50–65%).
• Shorter duration of current episode: Patients with episodes lasting less than 12 months have higher response rates than those with chronic episodes exceeding 2 years.
• Fewer failed medication trials: Greater medication resistance predicts lower (though still meaningful) ECT response rates. The CORE study (Petrides et al., 2001) found that medication resistance was associated with a remission rate of approximately 48% versus 65% for medication-non-resistant patients.
• Older age: Older adults generally respond at least as well as, and often better than, younger adults to ECT. This may reflect a higher prevalence of melancholic and psychotic features in late-life depression.
• Melancholic features: Including psychomotor disturbance, diurnal variation, and neurovegetative symptoms — historically the strongest clinical predictors, though the specificity of melancholia as a predictor has been questioned.
• Catatonic features: Robust predictor across diagnostic categories.

Negative Predictors

• Personality disorder comorbidity: Particularly borderline personality disorder, associated with lower response rates and higher relapse rates
• Chronic depression: Duration exceeding 2 years predicts attenuated response
• High medication resistance: Failure of 3+ adequate trials, though ECT still offers benefit to a substantial proportion of these patients
• Prominent anxiety features: Comorbid anxiety may attenuate ECT response, though data are mixed
• Substance use disorders: Active substance use complicates both treatment delivery and outcome assessment

Biomarker Predictors (Research Stage)

Neuroimaging biomarkers are under active investigation. Pre-treatment hippocampal volume, anterior cingulate cortex activity, and functional connectivity patterns have shown promise as predictors of ECT response in preliminary studies. The GEMRIC consortium is conducting the largest neuroimaging study of ECT to date, aggregating structural and functional MRI data from over 20 international sites to identify reliable predictive biomarkers. While promising, no imaging or biological biomarker has yet been validated for clinical use in ECT treatment selection.

ECT use in specific populations requires tailored risk-benefit analysis and procedural modifications.

Older Adults

Elderly patients represent the largest demographic group receiving ECT in many countries. ECT is effective and generally safe in older adults, with response rates comparable to or exceeding those in younger populations. However, older adults are at greater risk for cognitive side effects (particularly retrograde amnesia), post-ECT delirium, and cardiovascular complications. Ultra-brief pulse, right unilateral electrode placement, and twice-weekly scheduling are particularly important risk-mitigation strategies in this population. Concurrent anticholinergic medications should be minimized. Despite these considerations, ECT remains one of the best-tolerated and most effective treatments for severe late-life depression, particularly given that elderly patients often have limited pharmacotherapy options due to medication side effects and drug interactions.

Pregnancy

ECT is considered one of the safest treatments for severe depression and psychosis during pregnancy, particularly when the risks of pharmacotherapy to the fetus or the risks of untreated illness to both mother and fetus are substantial. Large case series report no increase in congenital malformations, miscarriage, or preterm labor attributable to ECT. The primary precautions include fetal monitoring during and after the procedure, left lateral positioning to prevent aortocaval compression in the second and third trimesters, aspiration prophylaxis with a non-particulate antacid, and obstetric consultation.

Adolescents and Children

ECT is used rarely in adolescents and very rarely in children, typically reserved for severe treatment-resistant depression, catatonia, or psychosis unresponsive to pharmacotherapy. Evidence is limited to case series and retrospective studies, but available data suggest efficacy and safety profiles comparable to those in adults. The APA recommends that ECT in patients under 18 should involve a second psychiatric opinion and thorough informed consent with both the patient and guardians.

Medical Comorbidities

Patients with dementia may receive ECT for co-occurring depression, though cognitive monitoring must be particularly vigilant, and baseline cognitive impairment may worsen transiently. In Parkinson's disease, ECT improves both motor symptoms and depression, likely through dopaminergic mechanisms. Patients with epilepsy can safely receive ECT — the anticonvulsant effects of ECT may paradoxically improve seizure control. Cardiac disease requires careful anesthetic management but is not a contraindication if appropriately managed.

Psychiatric comorbidities are the rule rather than the exception among ECT candidates, and they significantly influence treatment planning and outcomes.

Anxiety Disorders

Comorbid anxiety disorders are present in an estimated 40–60% of patients with MDD receiving ECT. Generalized anxiety disorder and panic disorder are the most common co-occurring conditions. Anxiety comorbidity has been associated with slower response to ECT in some studies, though meta-analytic evidence is limited. ECT does appear to reduce anxiety symptoms alongside depression, though dedicated anxiety-focused studies are rare.

Substance Use Disorders

Approximately 15–25% of patients receiving ECT have co-occurring substance use disorders. Active alcohol or benzodiazepine use raises seizure thresholds and may reduce ECT efficacy. Stimulant use increases cardiovascular risk. Patients should ideally be stabilized from acute intoxication or withdrawal before initiating ECT, though in emergency situations this may not be feasible.

Personality Disorders

Comorbid personality disorders, particularly borderline personality disorder (BPD), are associated with lower ECT response rates. A study by DeBattista and Mueller (2001) found that personality disorder comorbidity reduced remission rates by approximately 20 percentage points. This likely reflects both biological factors (personality pathology may indicate a different neurobiological substrate for depression) and psychosocial factors (interpersonal instability, non-adherence to continuation treatment).

Neurocognitive Disorders

Patients with mild cognitive impairment or early dementia who develop superimposed major depression may benefit from ECT, but they require particularly careful cognitive monitoring. Pre-ECT neuropsychological assessment is strongly recommended to establish a baseline against which post-treatment cognitive function can be compared.

Post-Traumatic Stress Disorder

PTSD comorbidity, present in an estimated 10–20% of ECT candidates, may affect both treatment response and the subjective experience of memory-related side effects. The experience of memory loss may be particularly distressing for trauma survivors. Sensitive clinical communication and trauma-informed consent processes are important in this subgroup.

Research into ECT continues to evolve across multiple domains, from technical optimization to biomarker development.

Focal Electrically Administered Seizure Therapy (FEAST)

FEAST is an experimental approach that uses unidirectional current and focal stimulation to initiate seizures in specific brain regions (typically the right prefrontal cortex) while minimizing current spread to temporal regions important for memory. Preliminary data suggest preserved efficacy with reduced cognitive effects, but randomized controlled trials are needed.

Magnetic Seizure Therapy (MST)

MST uses transcranial magnetic stimulation to induce a generalized seizure under anesthesia. Because magnetic fields can be focused more precisely than electrical currents, MST may produce the therapeutic effects of seizure induction with fewer cognitive side effects. Randomized trials comparing MST to ECT (e.g., Daskalakis et al., 2020) have demonstrated comparable efficacy with superior cognitive outcomes, though data remain preliminary and MST is not yet widely available.

Biomarker-Guided Treatment

The integration of neuroimaging, EEG, and genetic biomarkers into ECT treatment algorithms is a major research priority. EEG-based indices of seizure quality (e.g., postictal suppression index, seizure coherence) are being investigated as real-time markers of treatment adequacy. The GEMRIC consortium's large-scale neuroimaging initiative aims to identify structural and functional MRI predictors of response that could guide clinical decision-making — for example, identifying patients likely to respond to ECT versus those who might achieve comparable outcomes with less invasive neuromodulation.

Optimizing Continuation Treatment

Preventing relapse after successful ECT remains the greatest unmet need in ECT practice. Current research is exploring optimal combinations of maintenance ECT with pharmacotherapy, the role of lithium augmentation (building on the Sackeim et al., 2001 findings), and whether novel agents such as ketamine or esketamine might serve as effective continuation strategies after ECT response.

Addressing Stigma and Access

Despite its efficacy, ECT remains underutilized globally. Stigma among patients, families, and even clinicians is a significant barrier. The geographic maldistribution of ECT services — concentrated in academic medical centers and larger hospitals — limits access for rural populations and those in resource-limited settings. Research into telemedicine-guided ECT protocols and training programs for community hospitals aims to address these disparities.

Limitations of the Evidence Base

Important limitations of the ECT literature include: the difficulty of maintaining blinding in sham-controlled trials (anesthesiologists and some research staff are necessarily unblinded); heterogeneity in technical parameters across studies; relatively short follow-up periods in most trials; underrepresentation of minority populations; and the reliance on symptom rating scales that may not fully capture functional recovery or quality of life. Long-term cognitive outcome studies extending beyond 6–12 months are notably sparse, and this remains a critical gap in the literature.